ClinicalTrials.gg
RecruitingNCT05532813METFORMYOUpdated Nov 24, 2025

Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease)

A Phase 3 interventional study of Treatment taken in Steinert's Disease, Myotonic Dystrophy 1 and Metformin, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Myotonic Dystrophy with a site in France — 10 open to participants now, 13 under way, 4 of them phase 3. Myotonic Dystrophy · France.

Planned enrollment
5th of 20
142 · median 76
Started
2024
with 5 others
Phase 3
7 of 30
4 open now
Primary completion
2026-11
later than 1 of 12 live
Registered
17th of 30
by date
Lead sponsor
4 of 30
Assistance Publique - Hôpitaux de Paris

Among the 30 studies in Myotonic Dystrophy with a site in France, this one is the 5th largest by planned enrollment of the 20 interventional ones that give a count, is one of 6 that started in 2024, is one of 7 in phase 3, reaches primary completion later than 1 of the 12 other live ones, and was the 17th registered.

Myotonic Dystrophy

127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.

Browse Myotonic Dystrophy studies →

Open to participants now

10 of the 30 studies in Myotonic Dystrophy with a site in France are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Myotonic Dystrophy with a site in France, or all of them as a file.
02

Study summary

The study team hypothesize that non-diabetic patients with Myotonic dystrophy type I (DM1) will improve their symptoms, especially their motor deficit which is the main feature of the disease, because of the splicing defect correction by metformin.

The primary objective of the study is to evaluate the efficacy of metformin vs placebo, on the improvement of muscle function in patients with DM1 compared to its placebo.

As the secondary objectives, the study aims:

  • To evaluate the safety of metformin on patient with DM1.
  • To evaluate the efficacy of metformin vs placebo on:

    1. The hand-grip strength;
    2. The thumb-index pinch strength;
    3. The locomotor function;
    4. The respiratory function;
    5. The cardiac function;
    6. The quality of life;
    7. The daily and social activity.
Read the detailed description

This is a multicenter, national, comparative study comparing the efficacy and safety of metformin and placebo in patients (1:1 ratio between the 2 groups) with DM1.

Population of study participants: patients with biochemically and/or genetically confirmed DM1 disease already followed in the referral and competence departments, as well as new patients.

All patients will be included by a neuromuscular specialist from French centers participating in the research.

Enrolled patients were randomly assigned (71 patients per group with 1:1 ratio) to either metformin therapy or a placebo, using a centralized randomization procedure.

Metformin or placebo will be administered orally and titrated as recommended in diabetic patients. Initial digestive effects (nausea, vomiting and constipation) of metformin that can be observed in the first days. If digestive tolerance is good, treatment will be increased to a maximum of 1000 mg three times a day i.e. 3000 mg/day after another week. In case of bad digestive tolerance, the dosage should be decrease and the maximum tolerated dosage of metformin should be used. The evaluations of muscle function, walking test, respiratory and cardiac function, quality of life, and tolerance will be assessed at M6 and M12, in the neuromuscular centers. With the estimated effect size, we believe that the inclusion capacities evaluated at 8 to 12 patients per center over one year (18 reference centers involved) will allow to determine a significant difference of MFM score 12 months after inclusion. Dose titration, monitoring of side effects and dose adjustments will be assessed at each visit according to the site endocrinologist advice, if necessary.

Statistical analysis: The difference between the score at 12 months and baseline will be compared between treatment groups using the Student T-test.

Secondary efficacy endpoints evaluating the evolution of symptoms will be analyzed using either a GMM or a GEE for continuous and categorical variables, respectively.

Other quantitative variables will be compared using the Student t-test (or a non-parametric test if the distribution remains skewed following transformation), while categorical variables will be analyzed using either the Chi-squared or the Fisher-exact tests.

All efficacy endpoints will be analysed on an intention-to- treat basis and safety endpoints on a per-protocol basis.

All statistical tests will be performed with a level of significance of 5%. No interim analysis will be performed.

03

Conditions studied

  • Steinert's Disease
  • Myotonic Dystrophy 1
  • Metformin

Browse trials for

Keywords

  • Steinert's Disease
  • Myotonic Dystrophy 1
  • Metformin
  • Muscle function
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • DM1 disease confirmed by genetic analysis
  • Men and women between 18 and 70 years of age.
  • Preserved walking abilities (stick assistance possible)
  • MIRS score 3 or 4
  • Women of under efficient during treatment
  • Patient able to consent
  • All patients who have completed and signed the specific information and form
  • Affiliation to a social security system

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast-feeding women
  • Men with an intention to conceive a child during the time of the study
  • to Metformin ( to metformin or to one of the )
  • Respiratory:

    • Patient requiring tracheotomy or
    • Patient requiring non-invasive-ventilation: - more than 12 hours per day; - insufficiently ventilated
  • inferior to 50 ml/min
  • Cardiac:

    • below 35%
    • Conduction system disease on the with PR interval >200 ms or QRS duration >110 ms without a pacemaker or an implantable defibrillator or cardiac electrophysiological study performed over the past 5 years
    • Third-degree or Second degree type II atrioventricular block without a pacemaker or an implantable defibrillator
    • Sustained ventricular tachycardia
  • Acute disease that may lead to tissue hypoxia
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
142 participants (estimated)

Study arms

  • Experimental
    Metformin arm

    Patients randomized in Metformin arm will take metformin orally.

    Drug: Treatment taken

  • Placebo comparator
    Placebo receivers

    Patients randomized in placebo arm will take placebo orally in the same procedure as metformin taken.

    Drug: Treatment taken

Interventions

  • DrugTreatment taken

    Treatment (Metformin or placebo) will be administered orally and titrated following the same guideline that metformin in diabetic patient: start with a daily dose of 500 mg twice a day, given during or after meals; then increase to 1000 mg twice a day after a week. If digestive tolerance is good, treatment will be increased to a maximum of 1000 mg three times a day i.e. 3000 mg/day after another week.

06

What researchers measure

Primary outcomes

  1. Change of muscle function

    By MFM (Motor Function Measure) scale. The MFM-32 is a widely used sensitive and reliable quantitative functional motor scale, validated for use in various neuromuscular disorders (Bérard et al. 2005) and presenting the advantage to measure precisely, not only the muscle strength but motor function which is the main concern for DM1 patients.

    Time frame: at baseline and 12 months

Secondary outcomes

  1. Safety endpoint

    Any serious adverse event, especially lactic acidosis.

    Time frame: through study completion, an average of 30 month

  2. Change of muscle function between baseline and 6 months

    By the MFM (Motor Function Measure) scale.

    Time frame: at baseline and 6 months

  3. The hand-grip strength

    The hand-grip strength defined by the scores obtained using a manual dynamometry standardized (MyoGrip)

    Time frame: baseline, 6 and 12 months

  4. The thumb-index pinch strength

    The thumb-index pinch strength defined by the scores obtained using a standardized manual dynamometry (MyoPinch)

    Time frame: baseline, 6 and 12 months

  5. The locomotor function

    The locomotor function defined by the scores obtained using the 6 Minutes Walking Test.

    Time frame: baseline, 6 and 12 months

  6. The respiratory function

    The respiratory function, using pulmonary function tests, defined by the Supine Vital Capacity (VC).

    Time frame: baseline, 6 and 12 months

  7. The cardiac function

    The cardiac function, using transthoracic echocardiography, defined by the left ventricular ejection fraction.

    Time frame: baseline, 6 and 12 months

  8. Quality of life assessement

    The quality of life defined by the scores obtained using the quality of life in genetic neuromuscular disease questionnaire (QoLgNMD).

    Time frame: baseline, 6 and 12 months

  9. The difference between DM1-ActivC at baseline visit, the visit at 6 months and final visit

    The activity defined by the scores obtained using the DM1 activity and participation scale for clinical use (DM1-ActivC).

    Time frame: baseline, 6 and 12 months

07

Study locations

1 of 1 sites recruiting
  • Neurology Department, Raymond-Poincaré hospital - APHP
    Garches, 92380, France
    Recruiting
08

References and documents

Publications

  • Berard C, Payan C, Hodgkinson I, Fermanian J; MFM Collaborative Study Group. A motor function measure for neuromuscular diseases. Construction and validation study. Neuromuscul Disord. 2005 Jul;15(7):463-70. doi: 10.1016/j.nmd.2005.03.004. PubMed 16106528 ↗
  • Landfeldt E, Nikolenko N, Jimenez-Moreno C, Cumming S, Monckton DG, Faber CG, Merkies ISJ, Gorman G, Turner C, Lochmuller H. Change over time in ability to perform activities of daily living in myotonic dystrophy type 1. J Neurol. 2020 Nov;267(11):3235-3242. doi: 10.1007/s00415-020-09970-6. Epub 2020 Jun 15. PubMed 32542526 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Nov 2026, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2022
First posted
Sep 8, 2022
StartActual
Nov 29, 2024
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2026
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05532813
Responsible party
Sponsor
First posted
Sep 8, 2022
Start date
Nov 29, 2024
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 24, 2025

Study contacts

Pascal LAFORÊT, MD, PhD
Contact
pascal.laforet@aphp.fr
+33 (0)1 47 10 77 36
Pascal LAFORÊT, MD, PhD
principal investigator · Neurology Department, Raymond Poincaré Hospital, APHP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion